Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Releases

  • Webcast Image Webcast
    Spring Bank Pharmaceuticals at the 2019 Cantor Fitzgerald Global Healthcare Conference  (Replay)
    Thursday, October 03, 2019 10:05 am EDT
Toggle Summary Spring Bank Announces Interim Top-Line Results from the First Cohort of the Phase 2 Trial Evaluating Low-Dose Inarigivir Plus Vemlidy® in Chronic Hepatitis B Patients
7 of 30 patients were HBsAg responders with ≥ 0.5log₁₀ reduction Inarigivir 50mg plus Vemlidy® 25mg was generally safe and well tolerated at 12 weeks Evaluation of inarigivir 200mg and 400mg co-administered with Vemlidy is ongoing HOPKINTON, Mass. , Oct.
Toggle Summary Spring Bank to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York, NY
HOPKINTON, Mass. , Sept. 23, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin Driscoll ,
Toggle Summary Yale Cancer Center to Present on the Synergistic Relationship Between Intravenously-Administered SB 11285, Spring Bank’s STING Agonist Development Compound, and Radiation Therapy in Cancer at the 2019 ASTRO Annual Meeting
HOPKINTON, Mass. , Sept. 17, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Dr.
Toggle Summary Spring Bank Announces $20 Million Strategic Debt Financing Agreement with Pontifax Medison Finance
Significant investment demonstrates confidence in Spring Bank’s novel development programs Extends Spring Bank’s cash runway beyond the end of 2021 Accelerates HBV antisense and STING antagonist development programs HOPKINTON, Mass. , Sept. 04, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals,
Toggle Summary Spring Bank Announces Collaborative Research Agreement with University of Texas Southwestern Medical School for Evaluation of STING Antagonist Compounds
HOPKINTON, Mass. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has entered into
Toggle Summary Spring Bank Pharmaceuticals Reports Second Quarter 2019 Financial and Operational Results and Provides Business Development Update
HOPKINTON, Mass. , July 31, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced its financial results for
Toggle Summary Spring Bank Announces FDA Acceptance of IND Application for SB 11285, an IV-Administered STING Agonist, for the Treatment of Advanced Solid Tumors
IV-Administered SB 11285 Phase 1 Trial Planned to Initiate in Coming Weeks HOPKINTON, Mass. , July 29, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections,
Toggle Summary Spring Bank Announces Dosing of Inarigivir 400mg In Multiple HBV Studies
-  First Patient Dosed Ahead of Schedule in Inarigivir 400mg CATALYST 2 Trial  -  First Patient Completes Dosing in Inarigivir 400mg Intra-Hepatic Liver Biopsy Study    -  Ongoing Inarigivir + Tenofovir Alafenamide 25mg Co-Administration Trial Expanded to Include Inarigivir 400mg Cohort HOPKINTON,
Toggle Summary Spring Bank Announces Research Agreement with The National Institute of Allergy and Infectious Diseases to Evaluate HBV Antisense Oligonucleotide Compounds
HOPKINTON, Mass. , July 18, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has entered into
Toggle Summary Spring Bank Pharmaceuticals Announces Election of Pamela Klein, M.D., to its Board of Directors
HOPKINTON, Mass. , July 10, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Pamela Klein , M.D.,